Nichi-Iko Pharmaceutical Co., Ltd. (NHKFF) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - Specialty & Generic industria. La empresa tiene su sede en Toyama, Japan. El CEO actual es Shingo Iwamoto.
NHKFF tiene fecha de IPO 2020-05-26, 2,656 empleados a tiempo completo, cotiza en el Other OTC.
Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, and distributes various pharmaceutical products. It operates through two segments, Nichi-Iko Group and Sagent Group. The company primarily focuses on the production of generic drugs. It offers antidiabetic agents, antacids, antireflux agents, beta-blocker, hypnotic and sedative, angiotensin ? antagonist, angiotensin ? antagonist/diuretic combination, dyslipidaemic agent, and calcium antagonist products, as well as chemotherapeutic agents. The company also provides treatments for circulatory, digestive, respiratory, nervous system, allergies, and others. It supplies its products to medical institutions, including hospitals, clinics, dispensing pharmacies, etc. The company was formerly known as Nihon Iyakuhin Kogyo Co., Ltd. and changed its name to Nichi-Iko Pharmaceutical Co., Ltd. in 2005. Nichi-Iko Pharmaceutical Co., Ltd. was incorporated in 1947 and is headquartered in Toyama, Japan.
